Brokerages expect Henry Schein, Inc. (NASDAQ:HSIC) to announce earnings per share (EPS) of $1.01 for the current fiscal quarter, Zacks Investment Research reports. Ten analysts have provided estimates for Henry Schein’s earnings, with estimates ranging from $0.97 to $1.03. Henry Schein posted earnings of $0.88 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 14.8%. The firm is expected to report its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Henry Schein will report full year earnings of $4.10 per share for the current financial year, with EPS estimates ranging from $4.05 to $4.18. For the next fiscal year, analysts anticipate that the company will report earnings of $4.44 per share, with EPS estimates ranging from $4.10 to $4.54. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Henry Schein.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 8th. The company reported $0.95 EPS for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.03. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.18 billion. During the same quarter last year, the business earned $0.88 earnings per share. Henry Schein’s revenue was up 10.2% on a year-over-year basis.
Shares of NASDAQ HSIC opened at $72.90 on Tuesday. The company has a current ratio of 1.44, a quick ratio of 0.74 and a debt-to-equity ratio of 0.34. Henry Schein has a 52 week low of $62.56 and a 52 week high of $93.14. The firm has a market capitalization of $11.29 billion, a P/E ratio of 20.25, a P/E/G ratio of 1.74 and a beta of 1.00.
In other news, EVP Mark E. Mlotek sold 10,359 shares of Henry Schein stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $72.73, for a total transaction of $753,410.07. Following the sale, the executive vice president now directly owns 79,506 shares of the company’s stock, valued at $5,782,471.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul Brons sold 4,822 shares of Henry Schein stock in a transaction dated Monday, June 11th. The shares were sold at an average price of $72.93, for a total value of $351,668.46. Following the sale, the director now directly owns 20,889 shares in the company, valued at $1,523,434.77. The disclosure for this sale can be found here. Company insiders own 1.15% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Suntrust Banks Inc. lifted its stake in shares of Henry Schein by 27.8% in the first quarter. Suntrust Banks Inc. now owns 20,079 shares of the company’s stock worth $1,349,000 after acquiring an additional 4,371 shares during the period. Allianz Asset Management GmbH lifted its stake in shares of Henry Schein by 14.3% in the first quarter. Allianz Asset Management GmbH now owns 584,528 shares of the company’s stock worth $39,286,000 after acquiring an additional 73,176 shares during the period. Polar Asset Management Partners Inc. acquired a new position in shares of Henry Schein in the first quarter worth approximately $12,306,000. Amalgamated Bank lifted its stake in shares of Henry Schein by 9.7% in the first quarter. Amalgamated Bank now owns 22,884 shares of the company’s stock worth $1,538,000 after acquiring an additional 2,017 shares during the period. Finally, CIBC World Markets Inc. lifted its stake in shares of Henry Schein by 174.1% in the first quarter. CIBC World Markets Inc. now owns 13,005 shares of the company’s stock worth $874,000 after acquiring an additional 8,261 shares during the period. 96.65% of the stock is currently owned by institutional investors.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.